Kindeva Drug Delivery has completed its first registration batch on its groninger high-volume vial line.
This newly installed line is one of four that are forecasted to be installed at the CDMO's facility in the next 18 months.
This advancement highlights the CDMOs ability to cater to the demand of injectable fill-finish production, and marks a significant step in the company's expansion.
As well as the advancement in Kindeva's fill-finish production capabilities, the company has successfully completed Factory Acceptance Testing (FAT) on the first of two Optima syringe/cartridge filling lines, which are to be incorporated into the Bridgeton facility.
This line is expected to arrive on site by November 2024, and is estimated to be qualified for completion by the first quarter of 2025.
Kindeva aims to have both Optima lines fully qualified by the end of 2025, and production capacity will exceed 100 million units annually when this occurs.
Denis Johnson, Chief Operating Officer at Kindeva, commented: “The completion of the first registration batch at the Bridgeton facility represents a significant milestone. This is the first of four lines planned to be installed in the next 18 months."
"Further, the completion of our Factory Acceptance Testing on the first of two Optima filling lines is a great step forward for us, and we look forward to expanding our capabilities as a global CDMO."
